Atomoxetine once daily for 24 weeks in adults with attention-deficit/ hyperactivity disorder (ADHD)

Impact of treatment on family functioning

Linda Wietecha, Joel Young, Dustin Ruff, David Dunn, Robert L. Findling, Keith Saylor

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: To assess the efficacy of atomoxetine (ATX) and impact of treatment on family functioning in adults with ADHD. Methods: Adults with attention-deficit/hyperactivity disorder (ADHD) having both a spouse/partner and child were randomized to placebo (n = 234) or ATX (n = 268) for 24 weeks. Attention-deficit/hyperactivity disorder measures included the Conners Adult ADHD Rating Scale total ADHD Symptoms score and Clinical Global Impression-ADHD-Severity. Marital measures included the Dyadic Adjustment Scale and the Family Assessment Measure Dyadic Relationship Scale (FAM III). Parenting measures included the Parenting Stress Index, Alabama Parenting Questionnaire, and Parenting Sense of Competence Scale (PSCS). Results: Improvement was greater with ATX over placebo at 24 weeks on the Conners Adult ADHD Rating Scale (-16.43 vs -8.65; P < 0.001, repeated measures) and Clinical Global Impression (P < 0.001, last observation carried forward). Baseline-to-end point changes in marital and parenting measures were significant but not between treatment groups. Post hoc analyses showed significant interaction of treatment and impairment for the FAM III Task Accomplishment (patient) and Role Performance (patient and spouse) items and PSCS efficacy. Further stratification by sex or presence of a child with ADHD yielded significant interaction and treatment differences for the FAM III Task Accomplishment and the FAM III and Dyadic Adjustment Scale affective expression items, PSCS total score, Alabama Parenting Questionnaire Corporal Punishment, and Parenting Stress Index attachment items. Conclusions: Atomoxetine demonstrated significant ADHD symptom reduction over 24 weeks. Although both groups demonstrated baseline-to-end point changes on many marital and parenting measure items, there were no treatment differences. Maladaptive behaviors of long-standing ADHD may benefit from both medication and behavioral-psychosocial intervention.

Original languageEnglish
Pages (from-to)125-133
Number of pages9
JournalClinical Neuropharmacology
Volume35
Issue number3
DOIs
StatePublished - May 2012

Fingerprint

Parenting
Attention Deficit Disorder with Hyperactivity
Mental Competency
Therapeutics
Social Adjustment
Spouses
Placebos
Atomoxetine Hydrochloride
Punishment
Observation

Keywords

  • ADHD
  • adults
  • atomoxetine
  • family functioning

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Clinical Neurology

Cite this

Atomoxetine once daily for 24 weeks in adults with attention-deficit/ hyperactivity disorder (ADHD) : Impact of treatment on family functioning. / Wietecha, Linda; Young, Joel; Ruff, Dustin; Dunn, David; Findling, Robert L.; Saylor, Keith.

In: Clinical Neuropharmacology, Vol. 35, No. 3, 05.2012, p. 125-133.

Research output: Contribution to journalArticle

Wietecha, Linda ; Young, Joel ; Ruff, Dustin ; Dunn, David ; Findling, Robert L. ; Saylor, Keith. / Atomoxetine once daily for 24 weeks in adults with attention-deficit/ hyperactivity disorder (ADHD) : Impact of treatment on family functioning. In: Clinical Neuropharmacology. 2012 ; Vol. 35, No. 3. pp. 125-133.
@article{cc61fbb440f74254891837c9c2ac5ea3,
title = "Atomoxetine once daily for 24 weeks in adults with attention-deficit/ hyperactivity disorder (ADHD): Impact of treatment on family functioning",
abstract = "Objective: To assess the efficacy of atomoxetine (ATX) and impact of treatment on family functioning in adults with ADHD. Methods: Adults with attention-deficit/hyperactivity disorder (ADHD) having both a spouse/partner and child were randomized to placebo (n = 234) or ATX (n = 268) for 24 weeks. Attention-deficit/hyperactivity disorder measures included the Conners Adult ADHD Rating Scale total ADHD Symptoms score and Clinical Global Impression-ADHD-Severity. Marital measures included the Dyadic Adjustment Scale and the Family Assessment Measure Dyadic Relationship Scale (FAM III). Parenting measures included the Parenting Stress Index, Alabama Parenting Questionnaire, and Parenting Sense of Competence Scale (PSCS). Results: Improvement was greater with ATX over placebo at 24 weeks on the Conners Adult ADHD Rating Scale (-16.43 vs -8.65; P < 0.001, repeated measures) and Clinical Global Impression (P < 0.001, last observation carried forward). Baseline-to-end point changes in marital and parenting measures were significant but not between treatment groups. Post hoc analyses showed significant interaction of treatment and impairment for the FAM III Task Accomplishment (patient) and Role Performance (patient and spouse) items and PSCS efficacy. Further stratification by sex or presence of a child with ADHD yielded significant interaction and treatment differences for the FAM III Task Accomplishment and the FAM III and Dyadic Adjustment Scale affective expression items, PSCS total score, Alabama Parenting Questionnaire Corporal Punishment, and Parenting Stress Index attachment items. Conclusions: Atomoxetine demonstrated significant ADHD symptom reduction over 24 weeks. Although both groups demonstrated baseline-to-end point changes on many marital and parenting measure items, there were no treatment differences. Maladaptive behaviors of long-standing ADHD may benefit from both medication and behavioral-psychosocial intervention.",
keywords = "ADHD, adults, atomoxetine, family functioning",
author = "Linda Wietecha and Joel Young and Dustin Ruff and David Dunn and Findling, {Robert L.} and Keith Saylor",
year = "2012",
month = "5",
doi = "10.1097/WNF.0b013e3182560315",
language = "English",
volume = "35",
pages = "125--133",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Atomoxetine once daily for 24 weeks in adults with attention-deficit/ hyperactivity disorder (ADHD)

T2 - Impact of treatment on family functioning

AU - Wietecha, Linda

AU - Young, Joel

AU - Ruff, Dustin

AU - Dunn, David

AU - Findling, Robert L.

AU - Saylor, Keith

PY - 2012/5

Y1 - 2012/5

N2 - Objective: To assess the efficacy of atomoxetine (ATX) and impact of treatment on family functioning in adults with ADHD. Methods: Adults with attention-deficit/hyperactivity disorder (ADHD) having both a spouse/partner and child were randomized to placebo (n = 234) or ATX (n = 268) for 24 weeks. Attention-deficit/hyperactivity disorder measures included the Conners Adult ADHD Rating Scale total ADHD Symptoms score and Clinical Global Impression-ADHD-Severity. Marital measures included the Dyadic Adjustment Scale and the Family Assessment Measure Dyadic Relationship Scale (FAM III). Parenting measures included the Parenting Stress Index, Alabama Parenting Questionnaire, and Parenting Sense of Competence Scale (PSCS). Results: Improvement was greater with ATX over placebo at 24 weeks on the Conners Adult ADHD Rating Scale (-16.43 vs -8.65; P < 0.001, repeated measures) and Clinical Global Impression (P < 0.001, last observation carried forward). Baseline-to-end point changes in marital and parenting measures were significant but not between treatment groups. Post hoc analyses showed significant interaction of treatment and impairment for the FAM III Task Accomplishment (patient) and Role Performance (patient and spouse) items and PSCS efficacy. Further stratification by sex or presence of a child with ADHD yielded significant interaction and treatment differences for the FAM III Task Accomplishment and the FAM III and Dyadic Adjustment Scale affective expression items, PSCS total score, Alabama Parenting Questionnaire Corporal Punishment, and Parenting Stress Index attachment items. Conclusions: Atomoxetine demonstrated significant ADHD symptom reduction over 24 weeks. Although both groups demonstrated baseline-to-end point changes on many marital and parenting measure items, there were no treatment differences. Maladaptive behaviors of long-standing ADHD may benefit from both medication and behavioral-psychosocial intervention.

AB - Objective: To assess the efficacy of atomoxetine (ATX) and impact of treatment on family functioning in adults with ADHD. Methods: Adults with attention-deficit/hyperactivity disorder (ADHD) having both a spouse/partner and child were randomized to placebo (n = 234) or ATX (n = 268) for 24 weeks. Attention-deficit/hyperactivity disorder measures included the Conners Adult ADHD Rating Scale total ADHD Symptoms score and Clinical Global Impression-ADHD-Severity. Marital measures included the Dyadic Adjustment Scale and the Family Assessment Measure Dyadic Relationship Scale (FAM III). Parenting measures included the Parenting Stress Index, Alabama Parenting Questionnaire, and Parenting Sense of Competence Scale (PSCS). Results: Improvement was greater with ATX over placebo at 24 weeks on the Conners Adult ADHD Rating Scale (-16.43 vs -8.65; P < 0.001, repeated measures) and Clinical Global Impression (P < 0.001, last observation carried forward). Baseline-to-end point changes in marital and parenting measures were significant but not between treatment groups. Post hoc analyses showed significant interaction of treatment and impairment for the FAM III Task Accomplishment (patient) and Role Performance (patient and spouse) items and PSCS efficacy. Further stratification by sex or presence of a child with ADHD yielded significant interaction and treatment differences for the FAM III Task Accomplishment and the FAM III and Dyadic Adjustment Scale affective expression items, PSCS total score, Alabama Parenting Questionnaire Corporal Punishment, and Parenting Stress Index attachment items. Conclusions: Atomoxetine demonstrated significant ADHD symptom reduction over 24 weeks. Although both groups demonstrated baseline-to-end point changes on many marital and parenting measure items, there were no treatment differences. Maladaptive behaviors of long-standing ADHD may benefit from both medication and behavioral-psychosocial intervention.

KW - ADHD

KW - adults

KW - atomoxetine

KW - family functioning

UR - http://www.scopus.com/inward/record.url?scp=84861526922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861526922&partnerID=8YFLogxK

U2 - 10.1097/WNF.0b013e3182560315

DO - 10.1097/WNF.0b013e3182560315

M3 - Article

VL - 35

SP - 125

EP - 133

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 3

ER -